Please Subscribe to get a daily link to Pat's blog via email


Your privacy is important to us. We will never spam you and keep your personal data secure.


23 09, 2015

Update on ixazomib

Tags: , , , |4 Comments

Don't sleep on ixazomib. My sources tell me to expect a flood of positive data about Takeda's oral proteasome inhibitor (MLN9708) at this year's ASH in Orlando. We should get a glimpse of things to come at the 15th International Myeloma Workshop (IMW 2015) in Rome, Italy, from September 23 to 26, 2015. Ixazomib is

9 09, 2015

Ixazomib granted priority review by FDA

Tags: , , |0 Comments

The myeloma world doesn't stop spinning just because I'm waiting for test results. With so much excitement surrounding the immunotherapies elotuzumab and daratumumab, another promising new drug, ixazomib (MLN9708), is often overlooked. That's a mistake, especially for patients that have successfully responded to Velcade and/or Kyprolis. This morning the FDA granted the oral proteasome inhibitor

3 03, 2015

Kyprolis “superior” to Velcade?

Tags: , , , , |18 Comments

There has been a surprising amount of myeloma related news lately; the FDA's approval of panobinostat last week, and now the early release of data apparently showing that Kyprolis helps keep a relapsed patient's myeloma at bay longer than Velcade. My friends at Onyx (now part of Amgen) forwarded me the release announcing the news

13 02, 2015

BREAKING NEWS: A tale of two promising myeloma therapies

Tags: , , , , |6 Comments

I'm delaying a follow up post I've been working on, Reaching patients in need can be challenging, to bring you some important news concerning two important new drugs--ixazumib and SAR650984--and the companies that make them. Ixazomib first.  An oral proteasome inhibitor, ixazomib (MLN9708) was developed by Millinnium Pharmaceuticals in Cambridge, Massachusetts.  Early clinical trial results